Notoginsenoside R1 attenuates oxidative stress-induced osteoblast dysfunction through JNK signalling pathway

Xumin Li¹,²,³,⁴ | Haiyan Lin⁵ | Xiaorong Zhang²,⁴,⁶ | Richard T. Jaspers⁴ | Qihao Yu²,⁶ | Yinghui Ji¹,²,⁴ | Tim Forouzanfar³ | Dongyun Wang⁷ | Shengbin Huang¹,²,⁸ | Gang Wu³,⁸

¹Department of Prosthodontics, School and Hospital of Stomatology, Wenzhou Medical University, Wenzhou, PR China
²Institute of Stomatology, School and Hospital of Stomatology, Wenzhou Medical University, Wenzhou, PR China
³Department of Oral and Maxillofacial Surgery/Pathology, Amsterdam UMC and Academic Centre for Dentistry Amsterdam (ACTA), Vrije Universiteit Amsterdam (VUA), Amsterdam Movement Science, Amsterdam, The Netherlands
⁴Laboratory for Myology, Amsterdam Movement Sciences, Faculty of Behavioral and Movement Sciences, Vrije Universiteit Amsterdam (VUA), Amsterdam, The Netherlands
⁵Savaid Stomatology School, Hangzhou Medical College, Hangzhou, PR China
⁶Department of Endodontics, School and Hospital of Stomatology, Wenzhou Medical University, Wenzhou, PR China
⁷Stomatological Center, Peking University Shenzhen Hospital, Shenzhen, PR China
⁸Department of Oral Cell Biology, Academic Centre for Dentistry Amsterdam (ACTA), University of Amsterdam (VU) and Vrije Universiteit Amsterdam (VU), Amsterdam, The Netherlands

Abstract

Oxidative stress (OS)-induced mitochondrial damage and the subsequent osteoblast dysfunction contributes to the initiation and progression of osteoporosis. Notoginsenoside R1 (NGR1), isolated from Panax notoginseng, has potent antioxidant effects and has been widely used in traditional Chinese medicine. This study aimed to investigate the protective property and mechanism of NGR1 on oxidative-damaged osteoblast. Osteoblastic MC3T3-E1 cells were pretreated with NGR1 24 h before hydrogen peroxide administration simulating OS attack. Cell viability, apoptosis rate, osteogenic activity and markers of mitochondrial function were examined. The role of C-Jun N-terminal kinase (JNK) signalling pathway on oxidative injured osteoblast and mitochondrial function was also detected. Our data indicate that NGR1 (25 μM) could reduce apoptosis as well as restore osteoblast viability and osteogenic differentiation. NGR1 also reduced OS-induced mitochondrial ROS and restored mitochondrial membrane potential, adenosine triphosphate production and mitochondrial DNA copy number. NGR1 could block JNK pathway and antagonize the destructive effects of OS. JNK inhibitor (SP600125) mimicked the protective effects of NGR1 while JNK agonist (Anisomycin) abolished it. These data indicated that NGR1 could significantly attenuate OS-induced mitochondrial damage and restore osteogenic differentiation.
INTRODUCTION

Osteoporosis is defined as a systemic degenerative disease, which is characterized by dysregulation of bone formation and progressive bone micro-architectural deterioration.\(^1\) Osteoporosis largely increases the fracture risk of bone.\(^1,2\) One of the major pathogenic factors for osteoporosis is oxidative stress (OS)\(^3,4\)—a pathophysiological status with relatively overproduced reactive oxygen species (ROS) and insufficient anti-oxidative defence.\(^5\) Our meta-analysis of clinical data concludes that in postmenopausal women the status of OS is closely related to the decreased bone mineral density (BMD).\(^6\)

Osteoblasts are responsible for bone formation, playing a crucial role in maintaining BMD and bone microstructure.\(^7\) OS can significantly reduce osteoblast viability and activity, thereby diminishing osteoblast quantity and function,\(^8\) which leads to the onset and progression of osteoporosis.\(^7\) At subcellular level, ROS directly attack and cause damage to mitochondria—the most vulnerable target of ROS, which stimulates mitochondria to further generate and release ROS, forming a vicious circle and finally leading to mitochondrial dysfunction.\(^9\) Mitochondrial dysfunction forms a critical molecular mechanism accounting for the OS-induced osteoblast apoptosis.\(^10\) Mitochondrial dysfunction also further impairs osteoblastic bone formation function.\(^11\) Therefore, bioactive agents that can both relieve OS-induced mitochondrial dysfunction and restore osteoblast function are promising to treat osteoporosis.

One of such candidate bioactive agents is notoginsenoside R1 (NGR1), a natural triterpene saponin compound derived from the traditional Chinese herb Panax notoginseng.\(^12\) Firstly, NGR1 has a potent capacity in relieving cellular damages, thereby having a strong protective effect on different kinds of cells,\(^14-16\) from OS in several pathological situations. Furthermore, the anti-oxidative effect of NGR1 is largely attributed to its preventive effect on OS-induced mitochondrial dysfunction.\(^17,18\) On the other hand, NGR1 also has an invaluable property to promote osteoblast function—osteogenic differentiation.\(^19,20\) However, it remains to be elucidated whether NGR1 can prevent OS-induced mitochondrial dysfunction and restore osteoblast function.

C-Jun N-terminal kinase (JNK) is one of the three signalling pathways of mitogen-activated protein kinases (MAPKs) that mediate cellular responses to physiological and pathological stimuli.\(^21\) JNK pathway can be activated in response to ROS and mediates OS-induced mitochondrial dysfunction in primary cortical neurons.\(^22\) Furthermore, JNK activation by acetaminophen is also shown to inhibit mitochondrial bioenergetics\(^23\) and mitochondrial biogenesis\(^24\) in liver cells. Consistently, our preliminary experiment also showed that JNK signalling pathway is activated in osteoblast under OS stimulation. On the other hand, NGR1 has been shown to be capable of blocking JNK signalling pathway.\(^25\) Therefore, we hypothesized that NGR1 relieves OS-induced osteoblast dysfunction and mitochondrial damage through attenuating OS-induced JNK activation.

In the present study, we established an OS-induced osteoblast dysfunction model to explore (1) NGR1’s osteoblast protection against oxidative damage and (2) its underlying molecular mechanisms.

MATERIALS AND METHODS

Cell culture and treatment

The mouse pre-osteoblast MC3T3-E1 cells were purchased from ATCC and cultured in α-minimum essential medium (α-MEM; Gibco) with 10% foetal bovine serum (FBS; Gibco), 100 units/ml penicillin (Invitrogen) and 100 μg/ml streptomycin (Invitrogen) in a humidified atmosphere of 5% CO\(_2\) at 37°C. MC3T3-E1 cells were pretreated with 0–50 μmol/L NGR1 (Zelang) diluted by dimethyl sulphoxide (DMSO; Sigma) for 24 h. The final concentration of DMSO in all experiments was <0.5%. The other compounds’ treating conditions were as follows: Hydrogen peroxide (H\(_2\)O\(_2\)) (0.75 mM, Sigma) for 6 h; SP600125 (100 μmol/L; Sigma), Anisomycin (100 μmol/L; Sigma) pre-incubated for 1 h. Osteogenic medium (OM) used for osteogenic inducing contains basic medium, β-glycerol phosphate (10 mM; Sigma) and ascorbic acid (50 μg/ml; Sigma).

Cell viability

1 × 10\(^4\) MC3T3-E1 cells were seeded per well in 96-well plates and exposed to H\(_2\)O\(_2\) and/or indicated test compounds. 3(4,5-dimethyl thiazol-2-yl)-2,5-diphenyltetrazolium (MTT) colorimetric assay was used for cell viability examination as previously described.\(^8\)

Measurement of apoptosis by transferase dUTP nick end labelling (TUNEL) assay

3 × 10\(^4\) MC3T3-E1 cells were seeded per well in 48-well plates with coverslip. TUNEL staining was processed as previously described.\(^8\) The percentage of apoptotic cells was estimated by the TUNEL positive cell counts in total cells from random fields.
2.4 | Alkaline phosphatase (ALP) staining and ALP activity assay

3 x 10^4 MC3T3-E1 cells per well were seeded on 48-well plates and exposed to H_2O_2 and/or other test compounds for indicated time. Then, the medium was exchanged to OM for 7 days. ALP staining was performed as previously described. Each well was photographed using a stereomicroscope (Olympus). ALP activity was assayed as previously described and presented as the concentration per gram of protein ((mg/ml)/g protein). Protein concentration was determined using BCA protein assay (Thermo Fisher).

2.5 | Mineralization analysis

Mineralization of MC3T3-E1 cells was determined in 48-well plates using Alizarin red S staining (ARS) as previously described. Each well was photographed under stereomicroscope, and the mineralization area was quantified by Image J.

2.6 | Real-time polymerase chain reaction (rt-PCR)

30 x 10^4 MC3T3-E1 cells per well were seeded on 6-well plates and exposed to H_2O_2 and/or other test compounds for indicated time. Then, the medium was exchanged to OM for 7 days. Total RNA extraction and rt-PCR amplifications were performed as previously described. The sequences of specific primers were listed in Table 1.

2.7 | Measurement of mitochondrial membrane potential (MMP)

To assess MMP, cells were co-stained with tetramethylrhodamine methyl ester (TMRM, 100 nM, Life Technologies) and Mitotracker Green (Mitogreen, 100 nM, Life Technologies) for 30 min, as in our previous study. Images were captured under a fluorescence microscope (Leica DMIL). Excitation wavelengths were 543 nm for TMRM and 488 nm for Mitogreen. Post-acquisition processing was performed with Image J software for the quantification of fluorescent intensity.

2.8 | Measurement of mitochondrial superoxide production

Cellular superoxide production in mitochondria was detected using the MitoSOX™ Red mitochondrial superoxide indicator (Life Technologies) according to the manufacturer’s protocol and a previously published method. Briefly, adherent MC3T3-E1 cells from different groups were co-incubated with MitoSOX™ reagent working solution (5 μM) and Mitogreen (100 nM) at 37°C in the dark for 10 min. After incubation, cells were rinsed 3 times using warm Hank’s balanced salt solution containing Ca_2+/Mg_2+ (HBSS; Gibco). Images were captured under a fluorescence microscope (Leica DMIL). Excitation wavelengths were 543 nm for MitoSOX and 488 nm for Mitogreen. Post-acquisition processing was performed with Image J software for the quantification and measurement of fluorescent intensity.

2.9 | Detection of adenosine triphosphate (ATP) production

For the measurement of ATP level, whole-cell extracts were lysed in lysis buffer provided in the ATP assay kit (Beyotime). After centrifugation at 12,000 g for 5 min at 4°C, the supernatants were transferred to a new 1.5 ml tube for ATP analysis. The luminescence from a 100 μL sample was assayed in a luminometer (Molecular Devices) together with 100 μL of ATP detection buffer. A standard curve of ATP concentrations (1 nM–1 μM) was prepared from a known amount.

2.10 | Evaluation of mitochondrial DNA (MtDNA) copy number

MC3T3-E1 cells were lysed for total DNA extraction. rt-PCR was conducted with 40 ng DNA (OD260; NanoDrop). MtDNA copy number was measured by cytochrome c oxidase subunit 1 (COX-1) normalized with nuclear DNA products (β-actin). The sequences of specific primers were listed in Table 1.

**TABLE 1** Primers sequences for polymerase chain reaction (PCR)

| Gene                        | Forward primer (5'−3') | Reverse primer (5'−3') |
|-----------------------------|-----------------------|------------------------|
| Akp2 (ALP)                  | TGCCCTACTTTGTGTCGGTGAA| TCACCCGATGAGTTCACAATG  |
| Osteocalcin (OCN)           | AGCAGCTTGCCAGACACCTTA| TAGCCGCCAGTGCTTGACTAC  |
| Collagen I (COL I)          | ATGCCCGCACCTCAAGATG   | TGAGGCCACAGCCTGAGTA    |
| Runt-related transcription factor 2 (Runx2) | CACTGGGGATTGCAACAAAGA | TTTTAAACACGCCCAGTTC    |
| Glyceraldehyde−3-phosphate dehydrogenase (GAPDH) | TCACCCGACCTTCCCCTG | TACCCGGAGTCTGATCTAAC  |
| cytochrome c oxidase subunit 1 (COX-1) | ATGCCCTTCCTCTCCCTCGCA | CGTAGGTCATGCTGTTGCCC  |
| β-actin                     | CCATGTTCCTCACAATTTCC  | GGGCAACCTTCCAATATAT    |
2.11 Western blotting assay

For Western blotting assay, MC3T3-E1 cells were lysed with RIPA lysis buffer (Sigma) supplemented with protease and phosphatase inhibitors (Thermo Fisher). The following steps were performed as previously described. Anti-pJNK (1:2000, Cell Signaling) and anti-JNK (1:2000, Cell Signaling) were the primary antibodies used in this assay. The secondary horseradish peroxidase-conjugated anti-rabbit IgG antibody (1:4000, Invitrogen) was incubated for 1 h. Each protein band was quantified by Image J software, and the relative levels of pJNK to JNK were measured.

2.12 Statistical analyses

Each experiment was repeated in triplicate. Data were reported as mean ± standard deviation (SD). One-way analysis of variance (ANOVA) was carried out by GraphPad Prism Software (GraphPad Software). p values < 0.05 were recognized statistically significant.

3 | RESULTS

3.1 NGR1 attenuated $H_2O_2$-induced osteoblast apoptosis and dysfunction

The MTT test showed that, after being pre-incubated with NGR1 ranging from 10 to 50 μM, cell viability reduced by $H_2O_2$ was effectively recovered under the condition of 25 μM (Figure 1A). TUNEL staining and the TUNEL positive cell counting (Figure 1B, C) indicated a 40% decrease of apoptosis by treatment with NGR1. To evaluate the osteoprotective effect of NGR1, MC3T3-E1 cells were cultured in OM. ALP, as a biomarker of osteoblast function, was observed decreased in $H_2O_2$ group and recovered 21% by supplementing NGR1 in ALP staining and ALP activity test (Figure 1D, E). The osteogenic capability of mineralization examined by ARS was also significantly rescued by NGR1 (Figure 1F, G). Furthermore, expression levels of typical osteogenic marker genes (ALP, Osteocalcin (OCN), Collagen I (COL I) and Runt-related transcription factor 2 (Runx2)) in OS injured model decreased but largely recovered after NGR1 administration (Figure 1H).

3.2 NGR1 attenuated $H_2O_2$-induced osteoblast mitochondrial dysfunction

To further confirm the role of NGR1 on mitochondrial OS and dysfunction in $H_2O_2$-induced MC3T3-E1 cells dysfunction, we tested MMP, mitochondrial ROS (MtROS), ATP production and MtDNA copy number. We found out that NGR1 significantly restored MMP (Figure 2A, C), ameliorated MtROS generation (Figure 2B, D), and increased ATP production as well as MtDNA copy number (Figure 2E, F). Collectively, these results indicate that NGR1 exerts efficient anti-oxidative and mitochondria-protective effects.

3.3 NGR1 blocked JNK signalling pathway activated by $H_2O_2$

JNK signalling pathway activation was assessed by the expression of phosphorylated JNK compared with total JNK protein. According to the Western blot results, NGR1 significantly prevented phosphorylation of JNK by 46% (Figure 3A), and its blocking effect was similar to that of SP600125, the specific JNK inhibitor ($p = 0.8281$) (Figure 3B). However, the blocking effect of NGR1 was abolished by adding JNK agonist Anisomycin ($p > 0.05$ vs. $H_2O_2$ group) (Figure 3B). These results demonstrate that NGR1 effectively blocked $H_2O_2$-induced JNK signalling activation.

3.4 NGR1 prevented $H_2O_2$-induced osteoblast apoptosis and dysfunction by blocking JNK signalling pathway

To further investigate the protective effect of NGR1 and the role of JNK signalling pathway in OS-induced osteoblast injury. JNK inhibitor SP600125 and activator Anisomycin were used in MC3T3-E1 cells OS model. SP600125 rescued MC3T3-E1 cells viability and prevented $H_2O_2$-induced apoptosis, as observed in Figure 4A and TUNEL staining results (Figure 4B, C). Furthermore, the results of ALP staining (Figure 4D, E), ARS (Figure 4F, G) and osteogenic genes’ levels (Figure 4H) demonstrate that blocking JNK by SP600125 also recovered MC3T3-E1 cells’ osteogenic ability. These data showed a stronger protective effect of NGR1 than SP600125. However, reactivating JNK by Anisomycin eliminated these benefits significantly, which confirmed that osteoblast protection from NGR1 due to its blockage of JNK signalling pathway.

3.5 NGR1 promoted mitochondrial function recovery by blocking JNK signalling pathway

As shown in Figure 5A-D, SP600125 restored MMP and prevented MtROS generation induced by $H_2O_2$, which represented the recovery of mitochondrial status. Blocking JNK signalling by SP600125 also rescued ATP production and MtDNA copy number (Figure 5E, F), showing the recovery of mitochondrial energy generation and mitochondrial abundance. Notably, NGR1 showed a SP600125 similar mitochondrial protective capability before adding Anisomycin compromised those benefits. Thus, JNK signalling is pivotal in mitochondrial function recovery process of NGR1.
OS-induced mitochondrial damage and subsequent osteoblast dysfunction are revealed to contribute to the onset and development of osteoporosis. In this study, we show for the first time that NGR1 antagonizes OS-induced damage, restores osteoblast viability and osteogenic differentiation. At subcellular level, NGR1 significantly reduces OS-induced MtROS and restores mitochondrial function.
such as membrane potential, ATP production and MtDNA copy number. We further demonstrate a key role of JNK in OS-induced mitochondrial damage and osteoblast dysfunction. Finally, NGR1 could block JNK activation and protect osteoblast from oxidative damages. These data indicate that NGR1 can significantly attenuate OS-induced mitochondrial damage and restore osteogenic differentiation of osteoblast by suppressing JNK activation, thus bearing a promising potential in treating osteoporosis.

ROS consist of a number of diverse radical and non-radical oxygen species, such as superoxide anion (O$_2^-$), hydroxyl radical (OH')...
FIGURE 4 NGR1 prevented H\textsubscript{2}O\textsubscript{2}-induced osteoblast apoptosis and dysfunction by blocking JNK signalling pathway. (A) MC3T3-E1 cells were incubated with 25 \textmu M NGR1 for 24 h before treating with 0.75 mM H\textsubscript{2}O\textsubscript{2} for 6 h. SP600125 or Anisomycin was added 1 h before H\textsubscript{2}O\textsubscript{2} treatment. Cell viability was determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium (MTT) reduction. (B, C) Cells were stained for Transferase dUTP Nick End Labeling (TUNEL) (green). 4', 6-diamidino-2-phenylindole (DAPI) was used to stain the nuclei. Scale bars, 100 \textmu m. (D) MC3T3-E1 cells after indicated treatment were subjected to alkaline phosphatase (ALP) staining and (E) ALP activity test. (F) Mineralization area of MC3T3-E1 cells after osteogenic inducing for 4 weeks was determined by alizarin red S staining. (G) The quantification of mineralization area. (H) The levels of osteogenic marker genes were analysed by rt-PCR. Data are shown as mean ± SD. **p < 0.01, ***p < 0.001, ****p < 0.0001
and H$_2$O$_2$, which are originally generated during normal metabolism in mitochondria following the activation of various enzymes, such as nicotinamide adenine dinucleotide phosphate (NADPH) oxidase, cyclooxygenases (COXs) and various mitochondrial oxidases. 27,28 O$_2^-$ is regarded as the ‘primary’ ROS and generates ‘secondary’ more aggressive ROS after interacting with other molecules. In both physiological conditions, such as ageing, hormonal changes 29–32 and pathological conditions associated with exposure to drug, radiation, exogenous or endogenous toxins and inflammatory cytokines, 33–35 ROS override the intrinsic anti-oxidative defence mechanism, leading to OS. ROS initially attack and cause dysfunction to mitochondria, whose damage stimulates further production of ROS, thereby exacerbating OS. OS generates cellular damage due to lipid oxidation, structural alteration of the membranes, oxidation of proteins and nucleic acids; the damage may further extent to the organs and become systemic. 36 For example, the pathology of many metabolic disorders and degenerative diseases such as diabetes mellitus and neurological disorders are highly related to OS. 37–39 Similarly, ROS greatly affect the generation, survival and functions of osteoblast, which is revealed to contribute to the onset and development of osteoporosis. 4 

Among ROS, H$_2$O$_2$ is more stable than other forms and can be added exogenously, which makes it suitable to mimic OS microenvironment. 40 Thus, H$_2$O$_2$ is widely used to establish cell oxidative damage model. 41–43 Consistent with our previous reports, 8 we found that H$_2$O$_2$ administration significantly affected not only osteoblast viability and survival (Figure 1A–C), but also osteogenic differentiation, such as ALP expression (Figure 1D, E), osteoblastogenic marker genes levels (Figure 1H) and mineralization (Figure 1F, G). OS-induced osteoblast dysfunction is mainly initiated and exacerbated by mitochondrial dysfunctions. 44,45 Overproduction of ROS attacks mitochondrial outer and inner membrane causing mitochondrial permeability transition and inducing mitochondrial membrane depolarization accompanying with excessive MtROS production. 10,46 These damages further lead to the release of proapoptotic proteins, 47 thereby initiating an osteoblast apoptotic program. On the other hand, mitochondria are the largest factory for ATP synthesis 48 so as

![Figure 5](image-url)
to provide energy for cell activities, such as osteoblastic differentiation. In the current study, \( \text{H}_2\text{O}_2 \) caused a series of severe mitochondrial dysfunctions in osteoblast, such as mitochondrial membrane depolarization (Figure 2A, C), MtROS overproduction (Figure 2B, D) and ATP level reduction (Figure 2E), which was consistent to our previous findings. In this study, we further showed that \( \text{H}_2\text{O}_2 \) also significantly decreased MtDNA copy number (Figure 2F)—an indicator of mitochondrial abundance and mutation, which contributed new knowledge to OS-induced osteoblast dysfunction. Continuous efforts have been made to seek efficacious bioactive agents that can both potently restore mitochondrial functions and promote osteogenic activities.

One major resource for such bioactive agents is natural herb-derived small-molecule compounds, many of which bear a potent anti-oxidative property. Some of them have been used in the treatment of OS-mediated systemic diseases such as neurological disorders and diabetes mellitus. In addition, the bioactive agent to treat osteoporosis should also have a potent capacity of promoting osteogenesis. One of such small-molecule compounds is NGR1—the major bioactive agent of many Chinese medicines that applied in clinic. NGR1 has been used in clinic to manage various diseases, such as cerebrovascular and cardiovascular diseases. In animal studies, NGR1 has been proven to have various effective therapeutic functions, such as neuroprotection, anti-diabetes, certain organ protection, bone metabolism regulation, anti-cancer and osteoporosis, which can be largely attributed to its potent anti-apoptotic, anti-inflammatory and anti-oxidative properties. NGR1 has been shown to effectively protect various types of cells from oxidative damages triggered by other pathological factors, such as AGEs (advanced glycation end products), ischaemia-reperfusion injury and oxidized low-density lipoprotein. NGR1 can decrease ROS production and prevent protein and lipid peroxidation by improving the activities of antioxidant enzymes, such as superoxide dismutase (SOD), catalase and glutathione.

As expected, our current study also showed that NGR1 antagonized the \( \text{H}_2\text{O}_2 \)-induced OS, restored cell viability and decreased apoptosis rate of osteoblast (Figure 1A–C). In the meantime, since NRG1 also bears a potent pro-osteogenic property, we further tested its efficacy in OS microenvironment in this study. Our results showed that NGR1 could restore ALP level and activity (Figure 1D, E), extracellular mineralization (Figure 1F, G) and the levels of a series of osteoblastogenic marker genes (such as ALP, OCN, COL I and Runx2) (Figure 1H) that were suppressed by \( \text{H}_2\text{O}_2 \). Mechanistically, Zhang et al. showed that the anti-oxidative effects of NGR1 are mediated by a well-known transcriptional factor Nrf2 and its subsequent HO-1 signalling. On the other hand, the suppression of JNK is also shown to play an important role of NGR1 in protecting cells from OS damages. However, the exact role of JNK remains unveiled.

JNK is one of the three well-characterized MAPK pathways, which transduce extracellular signals and regulate various cell activities, such as cell proliferation, migration, differentiation and apoptosis. Serving as a critical stress-responsive pathway, JNK is directly involved in the mitochondrial-dependent pathway of apoptosis. In addition, activated JNK also leads to the impairment of mitochondrial function and the inactivation of JNK rescues the biogenesis of mitochondria, recovers mitochondrial respiration and ATP synthesis in many kinds of cells. These functional characteristics of JNK inspired us to hypothesize that NGR1 maintained mitochondrial function so as to prevent OS-induced osteoblast dysfunction through suppressing JNK activation. Consistent with previous studies, our data show that NGR1 reduces MtROS and restores MMP, ATP synthesis and MtDNA copy number in OS in vitro microenvironment (Figure 2), which confirms that NGR1 can restore mitochondrial function. We further show that NGR1 effectively blocks the JNK signalling (Figure 3). The critical role of JNK in mitochondrial functions was corroborated by the findings that JNK inhibitor (SP600125) mimicked while JNK agonist (Anisomycin) blocked the protective effects of NGR1 on osteoblast dysfunction and mitochondrial dysfunction against OS (Figures 4 and 5). With all these findings, we demonstrated that the blockage of JNK signalling pathway contributed to NGR1’s mitochondria and osteoblast protection in OS conditions.

In fact, it has been previously suggested that NGR1 regulates JNK signalling through various pathways. Firstly, JNK is an important signalling protein downstream of Protein kinase B (Akt), NGR1 treatment can increase the expression of phospho-Akt and reduce the activity of the JNK signalling pathway in rat brain hypoxic-ischaemic injury model. In addition, phospho-inositol requiring enzyme-1(IRE1) activates the JNK pathway, while NGR1 inhibits activation of phospho-IRE1 in primary cortical neuron. In lipopolysaccharide-triggered human lung fibroblast injury model, TAK1, also known as mitogen-activated protein kinase kinase kinase 7 (MAP3K7), activates the downstream JNK pathway, which can be downregulated by NGR1. MicroRNA like miR-132 is also involved in the NGR1-induced JNK signalling pathway blockade in different kinds of cells. Further studies should be performed to investigate the molecular mechanisms involved in the axis of NGR1-JNK-mitochondrial function.

One limitation in this study is the adoption of a mouse osteoblast cell line. Studies with primary human mesenchymal stem cells need to be performed before extrapolating the current findings to clinical situations. Furthermore, in our future study, we will perform a well-designed in vivo study to illustrate the therapeutic effect of NGR1 on osteoporosis.

## 5 Conclusion

NGR1 significantly attenuates OS-induced mitochondrial damage and restores osteogenic differentiation of osteoblast through the blockage of JNK signalling pathway. This finding revealed the molecular biological mechanisms for the preventing effect of NGR1 on OS-induced osteoblast dysfunction, which lays a theoretic foundation for the further application of NGR1 for the prevention and treatment of osteoporosis.
ACKNOWLEDGEMENTS
The authors would like to thank China Scholarship Council (No. 2018083300402); Zhejiang Provincial Natural Science Foundation of China (No. LY17H140010); National Natural Science Foundation of China (No. 31800808); Key Research and Development Plan of Zhejiang Province (No. 2021C04013) for financially supporting this study.

CONFLICTS OF INTEREST
The authors confirm that there are no conflicts of interest.

AUTHORS’ CONTRIBUTIONS
Xumin Li: Data curation (equal); Funding acquisition (equal); Writing-original draft (equal). Hailan Lin: Data curation (equal); Writing-original draft (equal); and Investigation (equal). Xiaorong Zhang, Qihao Yu and Yinghui Ji: Data curation (equal). Richard T. Jaspers: Supervision (equal); Validation (equal); and Writing-review & editing (equal). Tim Forouzanfar: Supervision (equal); Formal analysis (equal); and Project administration (equal). Dongyun Wang: Formal analysis (equal); and Funding acquisition (equal). Shengbin Huang: Supervision (equal); Project administration (equal); Investigation (equal); and Conceptualization (equal). Gang Wu: Supervision (equal); Project administration (equal); Funding acquisition (equal); Writing-review & editing (equal); and Conceptualization (equal).

DATA AVAILABILITY STATEMENT
The data sets generated for this study are available on request to the corresponding author.

ORCID
Gang Wu https://orcid.org/0000-0001-8941-2500

REFERENCES
1. Khosla S, Hofbauer LC. Osteoporosis treatment: recent developments and ongoing challenges. Lancet Diabetes Endocrinol. 2017;5(11):898-907. https://doi.org/10.1016/S2213-8587(17)30188-2
2. Yu F, Xia W. The epidemiology of osteoporosis, associated fragility fractures, and management gap in China. Arch Osteoporos. 2019;14(1):32. https://doi.org/10.1007/s11657-018-0549-y
3. A. Molnár G, Kun S, Sélley E, et al. Role of tyrosine isomers in acute and chronic diseases leading to oxidative stress—A review. Curr Med Chem. 2016;23(7):667-685.
4. Manolagas SC. From estrogen-centric to aging and oxidative stress: a revised perspective of the pathogenesis of osteoporosis. Endocr Rev. 2010;31(3):266-300. https://doi.org/10.1210/er.2009-0024
5. Jiang X, Liu Y, Liu X, et al. Over-expression of a cardiac-specific human dopamine D5 receptor mutation in mice causes a dilated cardiomyopathy through ROS over-generation by NADPH oxidase activation and Nrf2 degradation. Redox Biol. 2018;19:134-146. https://doi.org/10.1016/j.redox.2018.07.008
6. Zhou Q, Zhu Li, Zhang D, et al. Oxidative stress-related biomarkers in postmenopausal osteoporosis: A systematic review and meta-analyses. Dis Markers. 2016;2016:7067984. https://doi.org/10.1155/2016/7067984
7. Marie PJ, Kassem M. Osteoblasts in osteoporosis: past, emerging, and future anabolic targets. Eur J Endocrinol. 2011;165(1):1-10. https://doi.org/10.1530/EJE-11-0132
8. Li X, Chen Y, Mao Y, et al. Curcumin protects osteoblasts from oxidative stress-induced dysfunction via GSK3beta-Nrf2 signaling pathway. Front Bioeng Biotechnol. 2020;8:625. https://doi.org/10.3389/fbioe.2020.00625
9. Qin D, Zhang H, Zhang H, Sun T, Zhao H, Lee WH. Anti-osteoporosis effects of osteoking via reducing reactive oxygen species. J Ethnopharmacol. 2019;244:112045. https://doi.org/10.1016/j.jep.2019.112045
10. Bhat AH, Dar KB, Anees S, et al. Oxidative stress, mitochondrial dysfunction and neurodegenerative diseases; a mechanistic insight. Biomed Pharmacother. 2015;74:101-110. https://doi.org/10.1016/j.biopharma.2015.07.025
11. Cai WJ, Chen Y, Shi LX, et al. AKT-GSK3beta signaling pathway regulates mitochondrial dysfunction-associated OPAL1 cleavage contributing to osteoblast apoptosis: preventative effects of hydroxytyrosol. Oxid Med Cell Longev. 2019;2019:4101738. https://doi.org/10.1155/2019/4101738
12. Shares BH, Busch M, White N, Shum L, Eliseev RA. Active mitochondria support osteogenic differentiation by stimulating beta-catenin acetylation. J Biol Chem. 2018;293(41):16019-16027. https://doi.org/10.1074/jbc.RA118.004102
13. Liu H, Yang J, Yang W, et al. Focus on notoginsenoside R1 in metabolism and prevention against human diseases. Drug Des Devel Ther. 2020;14:551-565. https://doi.org/10.2147/DDDT.S240511
14. Zhang HS, Wang SQ. Notoginsenoside R1 inhibits TNF-alpha-induced fibronectin production in smooth muscle cells via the ROS/ERK pathway. Free Radic Biol Med. 2006;40(9):1664-1674. https://doi.org/10.1016/j.freeradbiomed.2006.01.003
15. Zhao J, Cui L, Sun J, et al. Notoginsenoside R1 alleviates oxidized low-density lipoprotein-induced apoptosis, inflammatory response, and oxidative stress in HUVECs through modulation of XIAP/ miR-211-3p/TRAF6 axis. Cell Signal. 2020;76:109781. https://doi.org/10.1016/j.cellsigbio.2020.109781
16. Zhang B, Zhang X, Zhang C, Shen Q, Sun G, Sun X. Notoginsenoside R1 protects db/db mice against diabetic nephropathy via upregulation of Nrf2-mediated HO-1 expression. Molecules. 2019;24(2):247. https://doi.org/10.3390/molecules24020247
17. Meng X, Wang M, Wang X, et al. Suppression of NADPH oxidase and mitochondrial-derived superoxide by Notoginsenoside R1 protects against cerebral ischemia-reperfusion injury through estrogen receptor-dependent activation of Akt/Nrf2 pathways. Free Radic Res. 2014;48(7):823-838. https://doi.org/10.3109/1071762.2014.911853
18. Zhou P, Xie W, Meng X, et al. Notoginsenoside R1 ameliorates diabetic retinopathy through PINK1-dependent activation of mitophagy. Cells. 2019;8(3):213. https://doi.org/10.3390/cells8030213
19. Liu YL, Lin Z, Guo J, et al. Notoginsenoside R1 significantly promotes in vitro osteoblastogenesis. Int J Mol Med. 2016;38(2):537-544. https://doi.org/10.3892/ijmm.2016.2652
20. Wang T, Wan D, Shao L, Dai J, Jiang C. Notoginsenoside R1 stimulates osteogenic function in primary osteoblasts via estrogen receptor signaling. Biochem Biophys Res Commun. 2015;466(2):232-239. https://doi.org/10.1016/j.bbrc.2015.09.014
21. Papa S, Choy PM, Bubici C. The ERK and JNK pathways in the regulation of metabolic reprogramming. Oncogene. 2019;38(13):2223-2240. https://doi.org/10.1038/s41388-018-0582-8
22. Zhou Q, Lam PY, Han D, Cadenas E. c-Jun N-terminal kinase regulates mitochondrial bioenergetics by modulating pyruvate dehydrogenase activity in primary cortical neurons. J Neurochem. 2008;104(2):325-335. https://doi.org/10.1111/j.1471-4159.2007.04957.x
23. Hanawa N, Shinohara M, Saberi B, Gaarde WA, Han D, Kaplowitz N. Role of JNK translocation to mitochondria leading to inhibition of mitochondrial bioenergetics in acetaminophen-induced liver injury. J Biol Chem. 2008;283(20):13565-13577. https://doi.org/10.1074/jbc.M708916200
24. Tan YL, Ho HK. Hypothermia advocates functional mitochondria and alleviates oxidative stress to combat acetaminophen-induced hepatotoxicity. Cells. 2020;9(11):2354. https://doi.org/10.3390/cells9112354
25. Wang Y, Tu L, Li Y, Chen D, Wang S. Notoginsenoside R1 protects against neonatal cerebral hypoxic-ischemic injury through estrogen receptor-dependent activation of endoplasmic reticulum stress pathways. J Pharmacol Exp Ther. 2016;357(3):591-605. https://doi.org/10.1124/jpet.115.230359
26. Dai P, Mao Y, Sun X, et al. Attenuation of oxidative stress-induced oleostearyl apoptosis by curcumin is associated with preservation of mitochondrial functions and increased Akt-GSK3βeta SIGNALING. Cell Physiol Biochem. 2017;41(2):661-677. https://doi.org/10.1007/11500-017-5974-5
27. Circu ML, Aw TY. Reactive oxygen species, cellular redox systems, and apoptosis. Free Radic Biol Med. 2010;48(6):749-762. https://doi.org/10.1016/j.freeradbiomed.2009.12.022
28. de Mochel NSR, Seronello S, Wang SH, et al. Hepatocyte NAD(P)H oxidases as an endogenous source of reactive oxygen species during hepatitis C virus infection. Hepatology. 2010;52(1):47-59. https://doi.org/10.1002/hep.23671
29. Finkel T, Holbrook NJ. Oxidants, oxidative stress and the biology of ageing. Nature. 2000;408(6809):239-247. https://doi.org/10.1038/35041687
30. Sendur OF, Turan Y, Tastaban E, Serter M. Antioxidant status in patients with osteoporosis: a controlled study. Joint Bone Spine. 2009;76(5):514-518. https://doi.org/10.1016/j.jbspin.2009.02.005
31. Lean JM, Jagger CJ, Kirstein B, Fuller K, Chambers TJ. Hydrogen sulfide protects against oxidative stress-induced apoptosis via PI3K/Akt and MAPK/ERK signaling pathways. Cell Signal. 2013;25(5):1126-1135. https://doi.org/10.1016/j.cellsig.2013.02.003
32. Fu C, Xu D, Wang CY, et al. Alpha-lipoic acid promotes osteoblastic formation in H2O2-treated MC3T3-E1 cells and prevents bone loss in ovariectomized rats. J Cell Physiol. 2015;230(9):2184-2201. https://doi.org/10.1002/jcp.24947
33. Choi EM, Suh KS, Lee YS. Lipoitgenin restores osteoblast damage through regulating oxidative stress and mitochondrial dysfunction. Phytother Res. 2014;28(6):880-886. https://doi.org/10.1002/ptr.5071
34. Kalani A, Kamat PK, Voor MJ, Tyagi SC, Tyagi N. Mitochondrial epigenetics in bone remodeling during hyperhomocysteinemia. Mol Cell Biochem. 2014;395(1–2):89-98. https://doi.org/10.1007/s11010-014-2114-3
35. Mao YX, Cai WJ, Sun XY, et al. RAGE-dependent mitochondria pathway: a novel target of silibinin against apoptosis of osteoblastic cells induced by advanced glycation end products. Cell Death Dis. 2018;9(6):674. https://doi.org/10.1038/s41419-018-0718-3
36. Pham NA, Robinson BH, Hedley DW. Simultaneous detection of mitochondrial respiratory chain activity and reactive oxygen in diglotton-permeabilized cells using flow cytometry. Cytometry. 2000;41(4):245-251.
37. Gao J, Feng Z, Wang X, et al. SIRT3/SOD2 maintains osteoblast differentiation and bone formation by regulating mitochondrial stress. Cell Death Differ. 2018;25(2):229-240. https://doi.org/10.1038/cdd.2017.144
38. Malik AN, Czajka A. Is mitochondrial DNA content a potential biomarker of mitochondrial dysfunction? Mitochondrion. 2013;13(5):481-492. https://doi.org/10.1016/j.mito.2012.10.011
39. AlBasher G, Abdel-Daim MM, Almeer R, et al. Synergistic antioxidant effects of resveratrol and curcumin against fipronil-triggered oxidative damage in male albino rats. Environ Sci Pollut Res Int. 2020;27(6):6505-6514. https://doi.org/10.1007/s11356-019-07344-8
40. Guo S, Xi X, Li J. Notoginsenoside R1: a systematic review of its pharmacological properties. Pharmazie. 2019;74(11):641-647. https://doi.org/10.1691/ph.2019.9534
41. Fan C, Chen Q, Ren J, et al. Notoginsenoside R1 suppresses inflammatory signaling and rescues renal ischemia-reperfusion injury in experimental rats. Med Sci Monit. 2020;26:e920442. https://doi.org/10.12659/MSM.920442
42. Fu C, Yin D, Nie H, Sun D. Notoginsenoside R1 protects HUVEC against oxidized low density lipoprotein (Ox-LDL)-induced atherogenic response via down-regulating miR-132. Cell Physiol Biochem. 2018;51(4):1739-1750. https://doi.org/10.1007/s00733-018-5330-7
43. Zhu L, Gong X, Gong J, et al. Notoginsenoside R1 upregulates miR-221-3p expression to alleviate ox-LDL-induced apoptosis, inflammation, and oxidative stress by inhibiting the TLR4/NF-kappaB pathway in HUVECs. Braz J Med Biol Res. 2020;53(6):e9346. https://doi.org/10.1590/1414-431x20209346
44. Tu L, Wang Y, Chen DI, et al. Protective effects of notoginsenoside R1 via regulation of the PI3K-Akt-mTOR/PI3K pathway in neonatal cerebral hypoxic-ischemic brain injury. Neurochem Res. 2018;43(6):1210-1226. https://doi.org/10.1007/s11064-018-2538-3
45. Bode AM, Dong Z. The functional contrariety of JNK. Mol Carcinog. 2007;46(8):591-598. https://doi.org/10.1002/mc.20348
46. Grynung K, Ma FY, Nikolic-Paterson DJ. The JNK signaling pathway in renal fibrosis. Front Physiol. 2017;8:829. https://doi.org/10.3389/fphys.2017.00829
58. Sun P, Gu L, Luo J, Qin Y, Sun L, Jiang S. ROS-mediated JNK pathway critically contributes to PFOS-triggered apoptosis in SH-SY5Y cells. *Neurotoxicol Teratol*. 2019;75:106821. https://doi.org/10.1016/j.ntt.2019.106821

59. Murata H, Khine CC, Nishikawa A, Yamamoto KI, Kinoshita R, Sakaguchi M. c-Jun N-terminal kinase (JNK)-mediated phosphorylation of SARM1 regulates NAD(+) cleavage activity to inhibit mitochondrial respiration. *J Biol Chem*. 2018;293(49):18933-18943. https://doi.org/10.1074/jbc.RA118.004578

60. Grassi D, Diaz-Perez N, Volpicelli-Daley LA, Lasmezas CI. Palpha-syn* mitotoxicity is linked to MAPK activation and involves tau phosphorylation and aggregation at the mitochondria. *Neurobiol Dis*. 2019;124:248-262. https://doi.org/10.1016/j.nbd.2018.11.015

61. He KE, Yan LI, Pan C-S, et al. ROCK-dependent ATP5D modulation contributes to the protection of notoginsenoside NR1 against ischemia-reperfusion-induced myocardial injury. *Am J Physiol Heart Circ Physiol*. 2014;307(12):H1764-H1776. https://doi.org/10.1152/ajpheart.00259.2014

62. Qian D, Shao X, Li Y, Sun X. Notoginsenoside R1 protects WI-38 cells against lipopolysaccharide-triggered injury via adjusting the miR-181a/TLR4 axis. *J Cell Biochem*. 2019;120(12):19764-19774. https://doi.org/10.1002/jcb.29282

63. Cong S, Xiang L, Yuan X, Bai D, Zhang X. Notoginsenoside R1 up-regulates microRNA-132 to protect human lung fibroblast MRC-5 cells from lipopolysaccharide-caused injury. *Int Immunopharmacol*. 2019;68:137-144. https://doi.org/10.1016/j.intimp.2018.12.065

64. Sun Y, Liu B, Zheng X, Wang D. Notoginsenoside R1 alleviates lipopolysaccharide-triggered PC-12 inflammatory damage via elevating microRNA-132. *Artif Cells Nanomed Biotechnol*. 2019;47(1):1808-1814. https://doi.org/10.1080/21691401.2019.1610414

How to cite this article: Li X, Lin H, Zhang X, et al. Notoginsenoside R1 attenuates oxidative stress-induced osteoblast dysfunction through JNK signalling pathway. *J Cell Mol Med*. 2021;25:11278-11289. https://doi.org/10.1111/jcmm.17054